Cellulolytic fungi, among other microorganisms, have demonstrated the highest potential in terms of enzymatic productivity, complexity and efficiency. Their strong capabilities to extracellularly secret enzymes into the media are of increasing interest to the industry. They have been successfully applied for the production of recombinant proteins in the AgroIndustrial and Food sectors, however they still have an untapped potential for the production of biologics for pharma, diagnostic and molecular biology sectors.

Novel advances in synthetic biology, multi-omics, functional genomics plus CRISPR strategies now facilitates the precise and rapid optimization of the strains for these applications.

One of the most advanced fungal platforms is C1. Dyadic International Inc.  has developed an industrially proven expression system based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), nicknamed C1. The C1 technology is a robust and versatile fungal expression system for gene discovery, development, and production of enzymes and other proteins. 53Biologics is the world-wide CDMO leader with more than 10 years of experience developing C1 strains and transferring production processes to the industry.

From a gene sequence, 53Biologics could work in the design of the constructs and expression vectors selecting the most yielding strategy. After the construction and screening, our team will obtain the best transformant for the overexpression of your protein of interest. Considering the experience of 53Biologics establishing, optimizing and transferring the production of proteins using fungal platforms to commercial scales, the production of the obtained transformants will be easily scaled up to liter and m3 volumes. Besides this, 53Biologics has strong experience processing the fermentation broths to recovery and final purification of the protein of interest. The overall process would require just several weeks from the sequence to the cell line establishment and the first protein samples generation.

53Biologics is optimistic about the potential of this kind of new platforms for the human & health pharma and diagnostic sectors, but if not we could develop in parallel other cell lines with others hosts benchmarking the best solution for your protein of interest.